Source comparison
MK-677 for Perimenopause Research: Practical Comparison
MK-677 (Ibutamoren) Ghrelin receptor agonist → pulsatile GH release → hepatic IGF-1 synthesis Sleep quality, lean mass, bone density, metabolic rate Sleep: 1–2 weeks; body composition: 8–12 weeks; bone markers: 12–24 weeks Oral daily dosing (20–25mg), typicall
This comparison does not assign a generated winner or score.
- MK-677 (Ibutamoren)
- Ghrelin receptor agonist → pulsatile GH release → hepatic IGF-1 synthesis
- Sleep quality, lean mass, bone density, metabolic rate
- Sleep: 1–2 weeks; body composition: 8–12 weeks; bone markers: 12–24 weeks
- Oral daily dosing (20–25mg), typically before bed
- Most promising for women prioritizing sleep restoration and body composition. Does not address vasomotor symptoms directly
- Bioidentical HRT (estradiol + progesterone)
- Direct estrogen/progesterone receptor activation
- Hot flashes, mood, vaginal atrophy, bone preservation
- Vasomotor: 2–4 weeks; bone: 6–12 months
- Transdermal patch or oral capsule
- Gold standard for vasomotor symptom control. Less effective for GH-dependent metabolic decline
- Resistance Training (3x/week)
- Mechanical loading → anabolic signaling in muscle/bone
- Lean mass, insulin sensitivity, functional strength
- Strength: 4–6 weeks; body composition: 12–16 weeks
- Structured progressive overload program
- Essential regardless of other interventions. Synergistic with MK-677 but insufficient alone to reverse GH decline
- Selective Estrogen Receptor Modulators (SERMs)
- Tissue-selective estrogen receptor modulation
- Bone density, breast cancer risk reduction
- Bone markers: 6–12 months
- Oral daily (raloxifene 60mg typical)
- Effective for bone but no effect on sleep, body composition, or cognitive symptoms